Hype against randomized trials for one topic, computed and dated 30 October 2026. It rates the topic, never a person, and gives no dosing and no sourcing.
The short version
107Kyearly wiki viewsEnglish Wikipedia, to 30 Sep 2026
210randomized-trial paperstyped on PubMed
511views per trial paperlower is better backed
Receipts check outthe verdictby the published rule
Tretinoin
Receipts check out
511yearly views per trial paper
hype107K views a yearproof210 trial papers
The trial record is deep next to the attention it gets.
English Wikipedia readers opened the Tretinoin article about 107K times in the year to 30 September 2026. PubMed holds 210 papers typed as randomized trials for it, which is 511 yearly views per trial paper. By the published rule that earns the verdict Receipts check out.
That is a statement about the gap between attention and trial record. It does not say whether Tretinoin works or whether it is safe for anyone.
Tretinoin is a prescription medicine in most forms and is listed here for education only.
How does it compare with the others?
Tretinoin next to the other fourhype above, proof below, read 30 October 2026
Top chart: attention. Bottom chart: randomized-trial papers typed on PubMed. The highlighted bar is Tretinoin. A big top bar over a small bottom bar is what the meter reads as hype ahead of the trials.